$DERM
Journey Medical Corp

2022 Q4 Form 10-K Financial Statement

#000141057823000485 Filed on March 31, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2022
Revenue $15.97M $73.67M
YoY Change -8.85% 16.69%
Cost Of Revenue $7.718M $30.78M
YoY Change -18.97% -4.08%
Gross Profit $8.248M $42.89M
YoY Change 3.2% 38.14%
Gross Profit Margin 51.66% 58.23%
Selling, General & Admin $13.99M $59.47M
YoY Change -7.11% 49.29%
% of Gross Profit 169.58% 138.64%
Research & Development $4.256M $10.94M
YoY Change 113.65% 299.53%
% of Gross Profit 51.6% 25.51%
Depreciation & Amortization $1.227M $4.277M
YoY Change
% of Gross Profit 14.88% 9.97%
Operating Expenses $18.24M $70.41M
YoY Change 7.0% 65.39%
Operating Profit -$9.995M -$27.52M
YoY Change 10.36% -21.11%
Interest Expense -$634.0K $2.019M
YoY Change -84.52% -71.3%
% of Operating Profit
Other Income/Expense, Net $0.00 -$2.048M
YoY Change -100.0% -72.62%
Pretax Income -$10.63M -$29.57M
YoY Change -20.77% -30.21%
Income Tax $13.00K $63.00K
% Of Pretax Income
Net Earnings -$10.64M -$29.63M
YoY Change -51.07% -32.65%
Net Earnings / Revenue -66.65% -40.22%
Basic Earnings Per Share -$1.69
Diluted Earnings Per Share -$0.60 -$1.69
COMMON SHARES
Basic Shares Outstanding 17.53M
Diluted Shares Outstanding 17.53M

Balance Sheet

Concept 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.00M $32.00M
YoY Change -34.8% -34.79%
Cash & Equivalents $32.00M
Short-Term Investments
Other Short-Term Assets $3.309M $3.309M
YoY Change 35.73% 35.61%
Inventory $14.16M $14.16M
Prepaid Expenses
Receivables $28.21M $28.21M
Other Receivables $0.00 $0.00
Total Short-Term Assets $77.68M $77.68M
YoY Change -8.06% -8.06%
LONG-TERM ASSETS
Property, Plant & Equipment $189.0K $189.0K
YoY Change 112.36% 110.0%
Goodwill
YoY Change
Intangibles $27.20M
YoY Change 116.67%
Long-Term Investments
YoY Change
Other Assets $95.00K $95.00K
YoY Change -36.67% -36.67%
Total Long-Term Assets $27.48M $27.48M
YoY Change 114.85% 114.86%
TOTAL ASSETS
Total Short-Term Assets $77.68M $77.68M
Total Long-Term Assets $27.48M $27.48M
Total Assets $105.2M $105.2M
YoY Change 8.1% 8.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $36.57M $36.98M
YoY Change 60.31% 58.05%
Accrued Expenses $19.39M $19.63M
YoY Change -14.71% -14.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $5.192M $5.192M
YoY Change -2.44% -2.04%
Total Short-Term Liabilities $66.83M $66.83M
YoY Change 29.48% 29.49%
LONG-TERM LIABILITIES
Long-Term Debt $19.83M $21.24M
YoY Change 446.62% 485.07%
Other Long-Term Liabilities $108.0K $108.0K
YoY Change 1250.0% 980.0%
Total Long-Term Liabilities $19.83M $21.35M
YoY Change 445.42% 486.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $66.83M $66.83M
Total Long-Term Liabilities $19.83M $21.35M
Total Liabilities $88.18M $88.18M
YoY Change 59.62% 59.63%
SHAREHOLDERS EQUITY
Retained Earnings -$68.50M
YoY Change 76.22%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.98M $16.98M
YoY Change
Total Liabilities & Shareholders Equity $105.2M $105.2M
YoY Change 8.1% 8.1%

Cashflow Statement

Concept 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$10.64M -$29.63M
YoY Change -51.07% -32.65%
Depreciation, Depletion And Amortization $1.227M $4.277M
YoY Change
Cash From Operating Activities -$3.836M -$13.53M
YoY Change 19.65% 520.54%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $20.00M
YoY Change -100.0% -300.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$20.00M
YoY Change -100.0% 100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 948.0K 16.46M
YoY Change -97.02% -68.96%
NET CHANGE
Cash From Operating Activities -3.836M -13.53M
Cash From Investing Activities 0.000 -20.00M
Cash From Financing Activities 948.0K 16.46M
Net Change In Cash -2.888M -17.08M
YoY Change -110.54% -141.82%
FREE CASH FLOW
Cash From Operating Activities -$3.836M -$13.53M
Capital Expenditures $0.00 $20.00M
Free Cash Flow -$3.836M -$33.53M
YoY Change 91.23% -528.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001867066
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 derm Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2021Q4 derm Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2022 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet
0
CY2021 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet
0
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-41063
CY2022 dei Entity Registrant Name
EntityRegistrantName
JOURNEY MEDICAL CORPORATION
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1879539
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
9237 E Via de Ventura Blvd
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 105
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Scottsdale
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
AZ
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
85258
CY2022 dei City Area Code
CityAreaCode
480
CY2022 dei Local Phone Number
LocalPhoneNumber
434-6670
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022 dei Trading Symbol
TradingSymbol
DERM
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
26440139
CY2022 dei Auditor Name
AuditorName
KPMG LLP
CY2022 dei Auditor Location
AuditorLocation
Short Hills, New Jersey
CY2022 dei Auditor Firm
AuditorFirmId
185
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32003000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49081000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28208000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23112000
CY2022Q4 us-gaap Inventory Net
InventoryNet
14159000
CY2021Q4 us-gaap Inventory Net
InventoryNet
9862000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3309000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2438000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
77679000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
84493000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
27197000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12552000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
189000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
89000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
95000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
150000
CY2022Q4 us-gaap Assets
Assets
105160000
CY2021Q4 us-gaap Assets
Assets
97284000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
36570000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
22812000
CY2022Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
413000
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
641000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19388000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22733000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
160000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
35000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
8000
CY2022Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2948000
CY2021Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
812000
CY2021Q4 derm Deferred Cash Payment Discount Current
DeferredCashPaymentDiscountCurrent
9000
CY2022Q4 derm Deferred Cash Payment Discount Current
DeferredCashPaymentDiscountCurrent
9000
CY2022Q4 derm Deferred Cash Payment Current
DeferredCashPaymentCurrent
4991000
CY2022Q4 derm Installment Payments Licenses Net Current
InstallmentPaymentsLicensesNetCurrent
2244000
CY2021Q4 derm Installment Payments Licenses Net Current
InstallmentPaymentsLicensesNetCurrent
4510000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
83000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
98000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
66832000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51614000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
180000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
180000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
19826000
CY2022Q4 derm Installment Payments Licenses Net Non Current
InstallmentPaymentsLicensesNetNonCurrent
1412000
CY2021Q4 derm Installment Payments Licenses Net Non Current
InstallmentPaymentsLicensesNetNonCurrent
3627000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
108000
CY2022Q4 us-gaap Liabilities
Liabilities
88178000
CY2021Q4 us-gaap Liabilities
Liabilities
55241000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
85482000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
80915000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68502000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38874000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16982000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
42043000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105160000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97284000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70995000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
63134000
CY2022 us-gaap Other Income
OtherIncome
2674000
CY2022 us-gaap Revenues
Revenues
73669000
CY2021 us-gaap Revenues
Revenues
63134000
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
30775000
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
32084000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10943000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2739000
CY2021 derm Research And Development Expense Related To Licenses Acquired
ResearchAndDevelopmentExpenseRelatedToLicensesAcquired
13819000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
59468000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
39833000
CY2021 derm Wire Transfer Fraud Loss
WireTransferFraudLoss
9540000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
101186000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
98015000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-27517000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-34881000
CY2022 derm Interest Income
InterestIncome
60000
CY2021 derm Interest Income
InterestIncome
2000
CY2022 us-gaap Interest Expense
InterestExpense
2019000
CY2021 us-gaap Interest Expense
InterestExpense
7034000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-89000
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-447000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2048000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7479000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29565000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-42360000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1634000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29628000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-43994000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.69
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.69
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.32
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.32
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17531274
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17531274
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10189844
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10189844
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10292000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2466000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2022 derm Sale Of Stock Stock Issuance Costs
SaleOfStockStockIssuanceCosts
1921000000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30615000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
21812000
CY2021 derm Stock Issued During Period Value Conversion Of Debt
StockIssuedDuringPeriodValueConversionOfDebt
16105000
CY2021 derm Adjustments To Additional Paid In Capital Extinguishment Of Related Party Payable
AdjustmentsToAdditionalPaidInCapitalExtinguishmentOfRelatedPartyPayable
112000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-43994000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
42043000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4425000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
142000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29628000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16982000
CY2022 us-gaap Profit Loss
ProfitLoss
-29628000
CY2021 us-gaap Profit Loss
ProfitLoss
-43994000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
284000
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
48000
CY2022 us-gaap Paid In Kind Interest
PaidInKindInterest
770000
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
781000
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
63000
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2572000
CY2022 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
0
CY2021 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
2845000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4277000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2474000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
88000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
86000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
4425000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2466000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1566000
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-447000
CY2021 derm Research And Development Licenses Acquired Expense
ResearchAndDevelopmentLicensesAcquiredExpense
13819000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5380000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-768000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1744000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8458000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
871000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
774000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-55000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
144000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
14343000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
20388000
CY2022 derm Increase Decrease In Account Payable Related Party
IncreaseDecreaseInAccountPayableRelatedParty
-228000
CY2021 derm Increase Decrease In Account Payable Related Party
IncreaseDecreaseInAccountPayableRelatedParty
1869000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3568000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1235000
CY2022 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
160000
CY2022 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
27000
CY2021 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-91000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-95000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-84000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13534000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2181000
CY2021 derm Payments To Acquire Research And Development Licenses
PaymentsToAcquireResearchAndDevelopmentLicenses
10000000
CY2022 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
20000000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20000000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
142000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
CY2021 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
9540000
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5000000
CY2021 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5300000
CY2021 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
18967000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
214000
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1996000
CY2022 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
5000000
CY2021 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
7000000
CY2022 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2864000
CY2021 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
6188000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32536000
CY2022 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
19763000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
371000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1550000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16456000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53016000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17078000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
40835000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49081000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8246000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32003000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49081000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
993000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
168000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
158000
CY2022 derm Deferred Payment For Asset Acquisition
DeferredPaymentForAssetAcquisition
4740000
CY2022 derm Right Of Use Assets In Exchange For Lease Liabilities
RightOfUseAssetsInExchangeForLeaseLiabilities
188000
CY2021 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
214000
CY2021 derm Stock Issuance Costs Incurred During Non Cash Or Partial Non Cash Transaction
StockIssuanceCostsIncurredDuringNonCashOrPartialNonCashTransaction
371000
CY2021 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
362000
CY2021 us-gaap Stock Issued1
StockIssued1
21812000
CY2021 derm Conversion Of Debt To Common Stock
ConversionOfDebtToCommonStock
16105000
CY2021 derm Conversion Of Placement Agent Warrants To Common Stock
ConversionOfPlacementAgentWarrantsToCommonStock
948000
CY2021 derm Conversion Of Contingent Payment Warrants To Common Stock
ConversionOfContingentPaymentWarrantsToCommonStock
3680000
CY2021 derm Extinguishment Of Related Party Payable Relates To Deferred Tax Assets
ExtinguishmentOfRelatedPartyPayableRelatesToDeferredTaxAssets
43000
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1. ORGANIZATION AND PLAN OF BUSINESS OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Journey Medical Corporation (collectively “Journey” or the “Company”) is a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The Company’s current product portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the U.S. The Company acquires rights to products and product candidates by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, the products through its exclusive field sales organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At of December 31, 2022 and 2021, the Company is a majority-owned subsidiary of Fortress Biotech, Inc. (“Fortress” or “Parent”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At December 31, 2022, the Company had $32.0 million in cash and cash equivalents as compared to $49.1 million at December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 30, 2022, the Company filed a shelf registration statement on Form S-3 (File No. 333-269079), which was declared effective by the Securities and Exchange Commission (“SEC”) on January 26, 2023. This shelf registration statement covers the offering, issuance and sale by the Company of up to an aggregate of $150.0 million of the Company’s common stock, preferred stock, debt securities, warrants, and units (the “2022 Shelf”). At December 31, 2022, $150.0 million remains available under the 2022 Shelf. In connection with the 2022 shelf, the Company has entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (“B. Riley”), relating to shares of the Company’s common stock. In accordance with the terms of the Sales Agreement, the Company may offer and sell up to 4,900,000 shares of its common stock, par value $0.0001 per share, from time to time through or to B. Riley acting as the Company’s agent or principal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 12, 2022, the Company entered into a third amendment of the loan and security agreement with EWB (the “Amendment”), which increased the borrowing capacity of the Company’s revolving line of credit to $10.0 million, of which $2.9 million was outstanding at December 31, 2022, and added a term loan not to exceed $20.0 million. Both the revolving line of credit and the term loan mature on January 12, 2026. In January 2022 and August 2022, the Company borrowed $15.0 million and $5.0 million, respectively, against the term loan. The term loans bear interest at a floating rate equal to 1.73% above the prime rate and are payable monthly. The term loans contain an interest-only payment period through January 12, 2024, with an extension through July 12, 2024, if certain covenants are met, after which the outstanding balance of each term loan is payable in equal monthly installments of principal, plus all accrued interest, through the term loan maturity date. The Company may elect to prepay all or any part of the term loan without penalty or premium, but the Company may not re-borrow any amount, once repaid. Any outstanding borrowing against the revolving line of credit bears interest at a floating rate equal to 0.70% above the prime rate. The Amendment includes customary financial covenants such as collateral ratios and minimum liquidity provisions. At December 31, 2022, the Company was in compliance with all applicable financial covenants under the Amendment. The remaining $7.1 million revolving line of credit is fully available to the Company without any restrictions, other than certain customary and ordinary closing conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company expects that expenses will increase substantially for the foreseeable future as it pursues business development opportunities, commercializes and markets new products and incurs additional costs associated with operating as a public company. To date, the Company has not been materially impacted by COVID-19; however, depending on the extent of the ongoing pandemic, it is possible that the Company, financial condition and results of operations could be materially and adversely affected by COVID-19 in the future. Additionally, the Federal Reserve has raised and is expected to continue to raise the federal funds interest rate throughout 2023 in its effort to take action against domestic inflation. Because the Company’s borrowings under the facility with EWB bear interest at a floating rate, rising interest rates affect the amount of the regular payments the Company is required to make to EWB. Accordingly, the Company may experience materially higher borrowing costs in future fiscal quarters than it historically has to date. The Company may require additional financing to pursue both development stage and commercial opportunities. In addition, The Company anticipates increased commercialization expenses related to the launch of newly acquired products, as well as increased costs related to development and regulatory approval of potential development stage product acquisitions, including DFD-29. As the Company continues to expand its product portfolio, it may need to fund possible future operating losses, and, if deemed appropriate, establish or secure through </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">additional third-party manufacturing for the Company’s products, and expanded sales and marketing capabilities related to recent product acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the next twelve months from the issuance of these financial statements, the Company will be able to fund our operations through a combination of existing cash and cash equivalents generated from operations, and the EWB borrowing facility. In addition, the Company may seek to raise capital through additional debt or equity financing, which may include sales of securities under the 2022 Shelf or under a new registration statement. If such funding is not available or not available on terms acceptable to the Company, the current plans for expansion of the product portfolio may be scaled back, limited or curtailed. The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance the Company’s capital structure.</p>
CY2022 derm Product Portfolio Number Of Branded Drugs
ProductPortfolioNumberOfBrandedDrugs
8
CY2022 derm Product Portfolio Number Of Authorized Generic Prescription Drugs
ProductPortfolioNumberOfAuthorizedGenericPrescriptionDrugs
3
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32000000.0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49100000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates made by management include provisions for coupons, chargebacks, wholesaler fees, prompt-pay discounts, specialty pharmacy discounts, managed care rebates, product returns, government rebates and other allowances customary to the pharmaceutical industry. Significant estimates made by management also include inventory realization, valuation of intangible assets, useful lives of amortizable intangible assets and share-based compensation. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p>
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on these deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s accounts receivable primarily represent amounts due from drug wholesalers and specialty pharmacies in the United States. The Company performs periodic credit evaluations of customers and does not require collateral. An allowance for doubtful accounts is maintained for potential credit losses based on the aging of accounts receivable, historical bad debts experience, and the customer’s current ability to pay its obligations to the Company. Accounts receivables balances are written off against the allowance when it is probable that the receivable will not be collected. See Note 17 for significant customers.</p>
CY2022 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
400000
CY2021 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
100000
CY2022 us-gaap Increase Decrease In Finished Goods And Work In Process Inventories
IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
400000
CY2021 us-gaap Increase Decrease In Finished Goods And Work In Process Inventories
IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
0
CY2022 derm Options Granted
OptionsGranted
P10Y
CY2022 derm Percentage Of Tax Positions Interest Rate
PercentageOfTaxPositionsInterestRate
0.50
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
6454000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
5572000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
395000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7739000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4290000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
14588000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
9862000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
429000
CY2022Q4 us-gaap Inventory Net
InventoryNet
14159000
CY2021Q4 us-gaap Inventory Net
InventoryNet
9862000
CY2022Q1 derm Product Portfolio Number Of Branded Drugs
ProductPortfolioNumberOfBrandedDrugs
8
CY2022Q4 derm Deferred Cash Payment Current
DeferredCashPaymentCurrent
5000000.0
CY2022Q4 derm Deferred Cash Payment Current
DeferredCashPaymentCurrent
5000000.0
CY2022Q4 derm Accrued Research And Development License Fees Current
AccruedResearchAndDevelopmentLicenseFeesCurrent
1404000
CY2021Q4 derm Accrued Research And Development License Fees Current
AccruedResearchAndDevelopmentLicenseFeesCurrent
870000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
334000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
37925000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10728000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
27197000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
19003000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6451000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12552000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15029000
CY2021 us-gaap Finite Lived Intangible Assets Purchase Accounting Adjustments
FiniteLivedIntangibleAssetsPurchaseAccountingAdjustments
-3000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2474000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12552000
CY2022 us-gaap Finite Lived Intangible Assets Purchase Accounting Adjustments
FiniteLivedIntangibleAssetsPurchaseAccountingAdjustments
18922000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4277000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
27197000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4300000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2500000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
4277000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4277000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
4277000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3064000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
7360000
CY2022Q4 derm Finite Lived Intangible Assets Excluding Assets Not Yet Placed In Service
FiniteLivedIntangibleAssetsExcludingAssetsNotYetPlacedInService
23255000
CY2022Q4 derm Finite Lived Intangible Assets Not Yet Placed In Service
FiniteLivedIntangibleAssetsNotYetPlacedInService
3942000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
27197000
CY2022 us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
13000000.0
CY2022Q4 derm Accrued Reserve For Product Returns Current
AccruedReserveForProductReturnsCurrent
3689000
CY2021Q4 derm Accrued Reserve For Product Returns Current
AccruedReserveForProductReturnsCurrent
3240000
CY2022Q4 derm Accrued Inventory Current
AccruedInventoryCurrent
112000
CY2021Q4 derm Accrued Inventory Current
AccruedInventoryCurrent
253000
CY2022Q4 derm Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q4 derm Accrued Coupon And Rebates Current
AccruedCouponAndRebatesCurrent
7604000
CY2021Q4 derm Accrued Coupon And Rebates Current
AccruedCouponAndRebatesCurrent
10603000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2586000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2702000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2627000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
3833000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
512000
CY2022Q4 derm Accrued Ipledge Program
AccruedIpledgeProgram
447000
CY2021Q4 derm Accrued Ipledge Program
AccruedIpledgeProgram
41000
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
229000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
585000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
450000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19388000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22733000
CY2022Q4 derm Installment Payments Licenses Gross Current
InstallmentPaymentsLicensesGrossCurrent
2500000
CY2022Q4 derm Installment Payments Licenses Gross Non Current
InstallmentPaymentsLicensesGrossNonCurrent
1500000
CY2022Q4 derm Installment Payments Licenses Gross
InstallmentPaymentsLicensesGross
4000000
CY2022Q4 derm Imputed Interest On Current License Payment
ImputedInterestOnCurrentLicensePayment
256000
CY2022Q4 derm Imputed Interest On Non Current License Payment
ImputedInterestOnNonCurrentLicensePayment
88000
CY2022Q4 derm Imputed Interest On License Payment
ImputedInterestOnLicensePayment
344000
CY2022Q4 derm Installment Payments Licenses Net Current
InstallmentPaymentsLicensesNetCurrent
2244000
CY2022Q4 derm Installment Payments Licenses Net Non Current
InstallmentPaymentsLicensesNetNonCurrent
1412000
CY2022Q4 derm Installment Payments Licenses Net
InstallmentPaymentsLicensesNet
3656000
CY2021Q4 derm Installment Payments Licenses Gross Current
InstallmentPaymentsLicensesGrossCurrent
5000000
CY2021Q4 derm Installment Payments Licenses Gross Non Current
InstallmentPaymentsLicensesGrossNonCurrent
4000000
CY2021Q4 derm Installment Payments Licenses Gross
InstallmentPaymentsLicensesGross
9000000
CY2021Q4 derm Imputed Interest On Current License Payment
ImputedInterestOnCurrentLicensePayment
490000
CY2021Q4 derm Imputed Interest On Non Current License Payment
ImputedInterestOnNonCurrentLicensePayment
373000
CY2021Q4 derm Imputed Interest On License Payment
ImputedInterestOnLicensePayment
863000
CY2021Q4 derm Installment Payments Licenses Net Current
InstallmentPaymentsLicensesNetCurrent
4510000
CY2021Q4 derm Installment Payments Licenses Net Non Current
InstallmentPaymentsLicensesNetNonCurrent
3627000
CY2021Q4 derm Installment Payments Licenses Net
InstallmentPaymentsLicensesNet
8137000
CY2022Q4 derm Area Of Property Under Lease
AreaOfPropertyUnderLease
3681
CY2022Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P25M
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
100000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
93000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
89000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
4000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
4000
CY2022 us-gaap Lease Cost
LeaseCost
97000
CY2021 us-gaap Lease Cost
LeaseCost
93000
CY2022 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
100000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022 derm Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1
CY2022Q4 derm Common Stock Voting Rights Ratio
CommonStockVotingRightsRatio
1.1
CY2021Q1 derm Preferred Stock Convertible Percentage Of Discount On Share Price
PreferredStockConvertiblePercentageOfDiscountOnSharePrice
0.075
CY2021Q1 derm Preferred Stock Convertible Number Of Trading Days Prior To Exchange
PreferredStockConvertibleNumberOfTradingDaysPriorToExchange
P10D
CY2021 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
91000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
188000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M6D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0625
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.040
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
92000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
102000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
9000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
203000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
191000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
27948000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
183000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
27765000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4425000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2466000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8618
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.8545
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.67
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9661393000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y8M4D
CY2022 derm Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue
0
CY2022 derm Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y6M10D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
141019000
CY2022 derm Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue
9805000
CY2022 derm Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodTotalIntrinsicValue
-17058000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
CY2022 derm Revenue From Contract With Customer Excluding Assessed Tax.
RevenueFromContractWithCustomerExcludingAssessedTax.
70995000
CY2021 derm Revenue From Contract With Customer Excluding Assessed Tax.
RevenueFromContractWithCustomerExcludingAssessedTax.
63134000
CY2022 us-gaap Other Income
OtherIncome
2674000
CY2022 us-gaap Other Income
OtherIncome
2674000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
63000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
67000
CY2022 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
63000
CY2021 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
67000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-6701000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-7829000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1737000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1474000
CY2022 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-8438000
CY2021 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-9303000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8438000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10870000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1634000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6553000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3113000
CY2022Q4 derm Deferred Tax Assets Amortization Of License Fees
DeferredTaxAssetsAmortizationOfLicenseFees
4951000
CY2021Q4 derm Deferred Tax Assets Amortization Of License Fees
DeferredTaxAssetsAmortizationOfLicenseFees
4760000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2462000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1293000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
667000
CY2022Q4 derm Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
48000
CY2021Q4 derm Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
25000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances
2988000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances
3573000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
574000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
505000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1152000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
193000
CY2022Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
322000
CY2021Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
41000
CY2022Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
13000
CY2021Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
12000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
20356000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
12889000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19307000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10870000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1049000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2019000
CY2022Q4 derm Deferred Tax Liabilities Return And Allowances
DeferredTaxLiabilitiesReturnAndAllowances
1001000
CY2021Q4 derm Deferred Tax Liabilities Return And Allowances
DeferredTaxLiabilitiesReturnAndAllowances
1996000
CY2022Q4 derm Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
48000
CY2021Q4 derm Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
23000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.04
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.04
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.05
CY2022 derm Effective Income Tax Rate Reconciliation Provision To Return Percent
EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent
0
CY2021 derm Effective Income Tax Rate Reconciliation Provision To Return Percent
EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.28
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.26
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.03
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.02
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.04
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17531274
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10189844
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21358453
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12784252

Files In Submission

Name View Source Status
derm-20221231_pre.xml Edgar Link unprocessable
0001410578-23-000485-index-headers.html Edgar Link pending
0001410578-23-000485-index.html Edgar Link pending
0001410578-23-000485.txt Edgar Link pending
0001410578-23-000485-xbrl.zip Edgar Link pending
derm-20221231.xsd Edgar Link pending
derm-20221231x10k.htm Edgar Link pending
derm-20221231xex21d1.htm Edgar Link pending
derm-20221231xex23d1.htm Edgar Link pending
derm-20221231xex31d1.htm Edgar Link pending
derm-20221231xex31d2.htm Edgar Link pending
derm-20221231xex32d1.htm Edgar Link pending
derm-20221231xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
derm-20221231_def.xml Edgar Link unprocessable
derm-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
derm-20221231x10k_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
derm-20221231_cal.xml Edgar Link unprocessable